Less than one year after BioTime subsidiary LifeMap Sciences spun off a mobile health company, LifeMap Solutions has embarked on a pilot study of its COPD Navigator with Mount Sinai Hospital, ...
Stem cell technology developer Cell Targeting has sold its assets to BioTime (AMEX:BTX) in a deal worth about $2.3 million. BioTime will pay $250,000 in cash as well as 262,000 shares of BioTime’s ...
BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced the signing of an exclusive sublicense agreement with ...
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on addressing degenerative diseases, announced today the submission of a design ...
BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced the signing of an exclusive sublicense agreement and a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback